

Patient Labeling 101

La Shawn Griffiths, MSHS-PH, BSN, RN
Sharon R. Mills, BSN, RN, CCRP
Acting Team Leaders, Senior Patient
Labeling Reviewers, DRISK



Patient Labeling

Consists of:

- Medication Guides (MG)
- Patient Package Inserts (PPI)
- Instructions for Use (IFU)



Medication Guides

Part 208 of 21 CFR

MG required if FDA determines one or more circumstances exist:

1. patient labeling could help prevent serious AEs
2. serious risks: could affect patient's decision to use
3. patient adherence to directions crucial to effectiveness



Medication Guides

FDA-approved patient labeling and a component of REMS

- Primarily for outpatient Rx products with serious & significant public health concerns
- Based on (not in conflict with) Professional Information (PI)
- Format and content
 - At least 10 point font
 - Written in nontechnical language
 - Specified section headings (Q & A)
 - relevant to drug product



Medication Guides

Distribution Requirements

- Mfrs must provide sufficient #s of MGs or means for the dispenser to produce
- Dispenser required to provide MG when product is dispensed



Medication Guides

- **In the past, a Medication Guide was approved and considered only part of labeling**
- **Now, any drug that requires a new Medication Guide is considered to have a REMS**
 - Some drugs with existing MGs may convert to a REMS if FDA determines that there is new safety information



A Few Words About Consumer Medication Information (CMI)

Consumer Medication Information (CMI):

- is information that is developed by third party companies, such as **First Databank Wolters Kluwer Health, and others.**
- is not part of FDA-approved labeling and is not reviewed by the Agency



Patient Labeling Review Process

- A collaborative effort between OND and OSE/DRISK
- DRISK is generally consulted by OND
- DRISK provides a formal review of patient labeling with recommended revisions
- DRISK works with OND to negotiate Patient Labeling with Applicants



Package Insert (PI)

MG = Medication Guide

PPI= Patient Package Insert

PIFU = Patient Instruction for Use

- Patient Labeling Reviewers rely on the PI to provide the basis for information that is included in patient labeling (PPI, MG, or PIFU)
- Review goal for PPI, MG, PIFU:
 - should be scientifically accurate, specific, and comprehensive, and should not conflict with PI information
 - weight given to and placement of information within patient labeling must be **consistent** with the weight given to and placement of information in the PI



Enhancing Readability of Patient Labeling Materials

General approaches to enhance readability:

- Patient labeling should be written at a 6 to 8th grade reading level
- Use of certain fonts: Verdana, Arial, or APFont size 11 or greater for better visibility
- Use of text boxes, bold font, and underlining to highlight important concepts
- Good use of white space, chunking, and bulleted formatting to enhance cognition



Patient Representative Q & A

We appreciate the questions that were forwarded to us for consideration.



Patient Representative Q & A (continued)

Many of the questions fall outside the scope of the Patient Labeling Team and should be addressed with OND. Examples:

- The PRO Guidance
- Inclusion of patient input regarding labeling
- Inclusion of quality of life issues in labeling
- Ensuring timely posting of updated labeling materials on the FDA web site, or timely distribution of updated printed materials



Patient Representative Q & A (continued)

Questions from Patient Representatives:

- Several Patient Representatives asked about including percentages of side effects and clinical trials statistics in patient labeling.



Patient Representative Q & A (continued)

- “Many of the materials are printed in pt. 2 type (or smaller!). Can FDA force the providers to make them legible w/o magnifying glasses?”



Patient Representative Q & A (continued)

- “Most patients do not read the labels if their doctor explained the drug and the side effects. Is there a way to print the label is such a way that it is Attractive to the reader?”



Patient Representative Q & A (continued)

- “Simply keeping track of the nomenclature (brand name, trade name, generic name, proprietary name, chemical name, etc.) is very confusing, even to professionals. FDA is making a real effort to remove such conflicts, but patients feel overwhelmed at times. Has any thought been given to creating some new system?”



Patient Representative Q & A (continued)

- “...how does this new drug I am about to start taking interacts with drugs I am already taking? In other words you should not take this drug with drugs X, Y, and Z.”



Patient Representative Q & A (continued)

“...I think it would be good to know, definitively, the process these pieces of information go through, the intended audience for each piece of information and then, ultimately how or if PRs (or anyone, for that matter) can weigh in and advocate for changes to be made to these informative pieces. ...in my field of interest, asthma, there are PPIs which exist where there is no consistency whatsoever. In one paragraph, this word or that phrase is used and in the very next paragraph, a different word or different phrasing is used. While this is not so difficult for one who is immersed in this disease and in the lingo, I know that this would be difficult for the average person to try and follow when the words and phrases change over and over w/in the same document. Not to mention those persons when English is not their first (or second) language.”



Thank you for your attention !



A photograph of several red, oval-shaped capsules scattered on a white surface. Some are in sharp focus in the foreground, while others are blurred in the background, suggesting a shallow depth of field. The capsules are arranged in a loose cluster, with one standing upright and others lying flat.

Anna M. Fine (Wojas), PharmD, MS

Office of Special Health Issues

U.S. Food and Drug Administration

Anna.Wojas@fda.hhs.gov

Prescription Drug Information

- Human Prescription for Drug and Biological Products
- A prescription drug product label is a compilation of information about a product written by the manufacturer and approved by FDA
- Final Rule, Requirements on Content and Format of Labeling for Human Prescription Drug and Biological Products became effective in June 2006

Adverse Event Reporting

Adverse Event Reports Comes IN to FDA

Food and Drug Administration



MEDWATCH

Safety Information Goes OUT to the Public

MedWatch History

FDA Safety Information and Adverse Event Reporting Program

1993 to 2009

2009 - MedWatch, The FDA **Safety Information** and Adverse Event Reporting Program

1998 - MedWatch, The FDA Medical Products Reporting and Safety Information Program



1993 - MedWatch, The FDA Adverse Event Reporting Program



Introducing MedWatch, DA Kessler, MD, *JAMA*, 269 (21): 2765, June 2, 1993.

“Our **goal is to...more widely disseminate information** of the FDA’s actions that have resulted from adverse event and product problem reporting..”

FDA Website

www.fda.gov/medwatch

www.hhs.gov

A-Z Index Search go

[Home](#) | [Food](#) | [Drugs](#) | [Medical Devices](#) | [Vaccines, Blood & Biologics](#) | [Animal & Veterinary](#) | [Cosmetics](#) | [Radiation-Emitting Products](#) | [Tobacco Products](#)

Safety

[Share](#) + [Email this page](#) ✉ [Print this page](#) 🖨 [Change Font Size](#) ⊕ ⊖

Home > Safety > MedWatch The FDA Safety Information and Adverse Event Reporting Program

MedWatch The FDA Safety Information and Adverse Event Reporting Program

[Safety Information](#)

[Reporting Serious Problems to FDA](#)

MedWatch: The FDA Safety Information and Adverse Event Reporting Program

Search MedWatch go

Your FDA gateway for finding clinically important safety information and reporting serious problems with human medical products.

What's New

- Natalizumab (marketed as Tysabri)
FDA continues to receive reports of progressive multifocal leukoencephalopathy (PML) in patients receiving Tysabri. Posted 09/17/2009
- Promethazine Hydrochloride Injection
Boxed Warning added to labeling, describing risks of severe tissue injury, including gangrene, following

Spotlight

- 2009 Safety Alerts for Human Medical Products
- Medical Product Safety Educational Resources
- MedWatch Widget
- MedWatch Partners

Resources for You

- Report a Serious Medical Product Problem Online
- Medical Product Safety Educational Resources
- DailyMed (National Institutes of Health)
- Medication Guides
- Index to Drug-Specific Information
- Current Drug Shortages
- MedWatch Safety Alerts

Recalls & Alerts

- MedWatch Safety Alerts for Human Medical Products
- FDA Patient Safety News Video Broadcasts
- FDA Drug Safety Newsletter

MedWatch Safety Information Out

MedWatch-issued product specific alerts

- FDA website
 - “your Internet gateway for timely safety information....”
- MedWatch Safety Alerts
 - Product-specific, timely and actionable alerts for drugs, biologics, devices and special nutritional products
- Monthly Drug Safety Labeling changes
 - 40-50 drugs with 80-100 changes/month to Boxed Warnings, Warning, Contraindications, Precautions, Adverse Reactions, Medication Guides

Monthly Safety Labeling Changes

- Clinically important safety labeling updates, including changes to the following labeling sections:
 - Boxed Warnings
 - Contraindications
 - Warnings and Precautions
 - Adverse Reactions
 - Patient Package Insert & Medication Guide
- In 2008:
 - 1157 safety changes
 - 561 PI's
 - 56 boxed warnings
 - 60 Medication Guides

Safety

Email this page Print this page Change Font Size

FDA Home > Safety > MedWatch The FDA Safety Information and Adverse Event Reporting Program > Safety Information

MedWatch The FDA Safety Information and Adverse Event Reporting Program

Safety Information

Safety-Related Drug Labeling Changes

January 2009
Drug Safety Labeling Changes

DRUG NAME <small>(Click on drug name to go to detailed view)</small>	SECTIONS MODIFIED					
	BW	C	W	P	AR	PPI/MG
Cimzia (certolizumab pegol)	X		X			X
<small>(Click on drug name to go to detailed view)</small>	BW	C	W	P	AR	PPI/MG
Avelox (moxifloxacin hydrochloride) Tablets, 400 mg			X		X	
Avelox (moxifloxacin hydrochloride in NaCl injection) I.V. - 150 mg/ml						
Celexa (citalopram hydrobromide) tablets			X			
Celexa (citalopram hydrobromide) solution						
Lexapro (escitalopram oxalate) Tablets						
Lexapro (escitalopram oxalate) oral solution						
Cymbalta (duloxetine hydrochloride) Delayed-Release Capsules 20, 30 and 60 mg			X			
Effxor XR (venlafaxine HCl) Extended-Release Capsules and Effxor (venlafaxine HCl) Tablets			X			
Hycodan (hydrocodone and homatropine) Tablets			X			

Monthly Safety Labeling Changes

U.S. Department of Health & Human Services www.hhs.gov

FDA U.S. Food and Drug Administration

Search go

FDA Home | Food | Drugs | Medical Devices | Vaccines, Blood & Biologics | Animal & Veterinary | Cosmetics | Radiation-Emitting Products

Safety

Email this page Print this page Change Font Size

FDA Home > Safety > MedWatch The FDA Safety Information and Adverse Event Reporting Program > Safety Information

MedWatch The FDA Safety Information and Adverse Event Reporting Program

Safety Information

Safety-Related Drug Labeling Changes

Celexa (citalopram hydrobromide) tablets January 2009
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- January 2009

The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. Read about the new physician labeling format.

Resources for You

- Prescribing Information

[Summary View](#)

Sections Modified	Summary of Changes to Contraindications and Warnings
<p>WARNINGS</p> <ul style="list-style-type: none"> Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like Reactions 	<p>WARNINGS</p> <ul style="list-style-type: none"> The development of a potentially life-threatening serotonin syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions have been reported with SNRIs and SSRIs alone, including Celexa treatment, but particularly with concomitant use of serotonergic drugs (including triptans) with drugs which impair metabolism of serotonin (including MAOIs), or with antipsychotics or other dopamine antagonists.....

MedWatch The FDA Safety Information and Adverse Event Reporting Program
Safety Information
Safety Alerts for Human Medical Products
Drug Safety Labeling Changes

Xenical (orlistat) capsules

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – May 2010

[Summary View](#)

PRECAUTIONS

General

- There have been rare postmarketing reports of severe liver injury with hepatocellular necrosis or acute hepatic failure in patients treated with orlistat with some of these cases resulting in liver transplant or death. Patients should be instructed to report any symptoms of hepatic

PATIENT PACKAGE INSERT

What are the possible risks of XENICAL?

- Xenical has been shown to reduce the absorption of certain vitamins. You should take a multivitamin containing vitamins D, E, K, and beta-carotene once a day at least 2 hours before or after the administration of Xenical, such as at bedtime.
- Some patients taking Xenical may develop an increased risk for the development of kidney stones. Promptly report any symptoms of back pain or blood in the urine.
- Some patients prescribed Xenical may already be at increased risk for the formation of gall stones. Weight loss with Xenical can increase the risk of gall stones. Promptly report any symptoms of pain in the upper right portion of the abdomen. The pain may be accompanied by nausea and vomiting.
- There have been rare reports of severe liver injury in patients taking Xenical. Promptly discontinue Xenical and contact your healthcare provider if you develop symptoms suggestive of liver impairment, such as loss of appetite, itching, yellowing of the skin, dark urine, light colored stools, or right upper quadrant pain.

ADVERSE Other

Rare
of
or
sy
Ve
inc
pa
an
orl
po
pa

Drugs@FDA



FDA Approved Drug Products

[FAQ](#) | [Instructions](#) | [Glossary](#) | [Contact Us](#)

[Drugs@FDA Demo](#) | [What's New in Drugs@FDA](#)

Search by Drug Name, Active Ingredient, or Application Number

Enter at least three characters:

Submit

Clear

[Advanced Search](#)

Browse by Drug Name

[A](#) [B](#) [C](#) [D](#) [E](#) [F](#) [G](#) [H](#) [I](#) [J](#) [K](#) [L](#) [M](#) [N](#) [O](#) [P](#) [Q](#) [R](#) [S](#) [T](#) [U](#) [V](#) [W](#) [X](#) [Y](#) [Z](#) [0-9](#)

[Drug Approval Reports by Month](#)

[Disclaimer](#)

FDA/Center for Drug Evaluation and Research
Office of Training and Communications
Division of Information Services
Update Frequency: Daily

[Start Over](#)

[Back to Search Results](#)

[Back to Details](#)

Label and Approval History

Drug Name(s)	ZETIA (Brand Name Drug)
FDA Application No.	(NDA) 021445
Active Ingredient(s)	EZETIMIBE
Company	MSP SINGAPORE

[Go to Approval History](#)

Label Information

[What information does a label include?](#)

Note: Not all labels are available in electronic format from FDA.

View the [label approved on 07/21/2009 \(PDF\)](#) for ZETIA, NDA no. 021445

- To see older, previously-approved labels, go to the "[Approval History](#)" section of this page. Older labels are for historical information only and should not be used for clinical purposes.

Approval History NDA 021445

Note: Not all reviews are available in electronic format from FDA.

Older labels are for historical information only, and should not be used for clinical purposes.

Approval dates can only be verified from 1984 to the present.

Click on a column header to re-sort the table:

Action Date	Supplement Number	Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note
07/21/2009	026	Labeling Revision	Label (PDF) Letter (PDF)	
07/21/2009	027	Labeling Revision	Label (PDF) Letter (PDF)	
01/27/2009	025	Package Change	Label (PDF) Letter (PDF)	

Other FDA-approved safety information

- DailyMed Current Labeling
 - An FDA/National Library of Medicine collaboration
 - <http://dailymed.nlm.nih.gov/dailymed/about.cfm>

Options

- Home
- E-mail Label Information
- Downloads
- SPL History
- Print this Label
- Notify of Updates
- Contact Us

Additional Resources

- Report Adverse Event
- MedlinePlus Information
- Find Clinical Trials
- Biochemical Data Summary
- Search PubMed Articles
- Presence in Breast Milk

Download the FDA official PDF of this label

Search By Drug Name:

Propafenone Hcl (propafenone hydrochloride) Tablet
[Watson Laboratories Inc.]

RxNorm Names

- [Review RxNorm Normal Forms](#)

Drug Label Sections

- Description
- Clinical Pharmacology
- Indications & Usage
- Contraindications
- Warnings
- Precautions
- Adverse Reactions
- Overdosage
- Dosage & Administration
- How Supplied
- Patient Counseling Information
- Supplemental Patient Material
- Boxed Warning
- Patient Package Insert
- Highlights
- Full Table of Contents
- Medication Guide

Mortality

In the National Heart, Lung and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multi-center, randomized, double-blind study in patients with asymptomatic non-life-threatening ventricular arrhythmias who had a myocardial infarction more than six days but less than two years previously, an increased rate of death or reversed cardiac arrest rate (7.7%; 56/730) was seen in patients treated with encainide or flecainide (Class 1C antiarrhythmics) compared with that seen in patients assigned to a placebo (3%; 22/725). The average duration of treatment with encainide or flecainide in this study was ten months.

The applicability of the CAST results to other populations (e.g., those without recent myocardial infarction) or other antiarrhythmic drugs is uncertain, but at present it is prudent to consider any 1C antiarrhythmic to have a significant risk in patients with structural heart disease. Given the lack of any evidence that these drugs improve survival, antiarrhythmic agents should generally be avoided in patients with non-life-threatening ventricular arrhythmias, even if the patients are experiencing unpleasant, but not life-threatening, symptoms or signs.

Patient Medication Information (PMI – aka CMI) The Single-Document Solution

PMI — Giving Patients the Information They Need

- Patients need easy access to prescription medication information (PMI) that is clear, concise, current, accurate, actionable, and accessible
- 2008 Evaluation of Consumer Medication Information
 - 94% consumers received information with new prescriptions
 - 75% met the criteria for usefulness
 - Demonstrating the PMI need is not being met

Current System

- **Patient Package Inserts (PPI)** - prescription information developed by manufacturers, approved by FDA and dispensed with specific products, e.g. oral contraceptives, estrogen-containing products
- **Consumer Medication Information (CMI)** - prescription drug information developed by pharmacies or an outside company, voluntarily distributed to consumers by pharmacies
- **Medication Guides** - prescription drug information for certain medications that “pose a serious and significant public health concern,” developed by the manufacturer, approved by FDA, and required to be distributed to consumers each time the medication is dispensed

A New Paradigm — The Single-Document Solution

- Over 22,000 marketed products requiring PMI
- Eliminate PPIs, CMI, and Medication Guides
- FDA will propose a new regulation
 - Require all prescription drugs to have a single PMI document
 - Describe the content and format
 - Define evaluation criteria and standards
 - Require manufacturers to consumer-test
- Source of PMI document – FDA approved professional labeling
- Manufacturers must develop, test, and submit PMI to an electronic repository

PMI Activities

- Feature *Rheutopia*, fictitious drug for RA and other conditions
 - Multiple indications and multiple serious risks
 - Unique administration (injection)
- Myriad of issues to be addressed, including:
 - Design Quality Management System for monitoring/evaluation with enforcement authority
 - Processes for evaluation
 - Submission and distribution
 - PMI repository and access
 - Interim solutions for phased-in implementation strategy

DRAFT PROTOTYPE 1
PATIENT INFORMATION**Rheutopia™ [Roo-toh-pee-ah] (also known as arixalate)****Important Warning: Serious Infections**

- Rheutopia affects the immune system. It can lower your ability to fight infections. Do not use Rheutopia if you have an active infection.
- People taking Rheutopia have gotten serious infections including tuberculosis (TB) and infections caused by viruses, fungi, or bacteria. Some people have died from these infections.

What Does Rheutopia Treat?

- Rheumatoid arthritis in adults. Rheutopia reduces painful and swollen joints, slows joint damage, and improves mobility and the ability to do physical activities.
- Polyarticular juvenile rheumatoid arthritis (JRA) in people older than 4 years of age who did not have good results from other medicines. Rheutopia reduces pain, improves mobility, and decreases the number of painful joints.
- Ankylosing spondylitis. Rheutopia reduces back pain, swelling, and improves mobility.
- Plaque psoriasis in adults who may benefit from taking medicine or receiving phototherapy (using ultraviolet light). Rheutopia improves or clears up areas of skin with psoriasis.

What Should I Tell My Doctor?

Before using Rheutopia, tell your doctor if you:

- have an infection, are being treated for an infection, or think you have an infection (such as a cold, flu or skin infection).
- have TB or have been near someone who has TB.
- lived in or traveled to other countries.
- have any nervous system or heart problems.
- are taking the medicine Kineret (anakinra).
- are scheduled to receive a vaccination (including a flu shot). You should not get a vaccination while taking Rheutopia.

When Should I Call My Doctor?

Stop using Rheutopia and tell your doctor right away if you develop:

- Fever, cough, flu-like symptoms, skin infection (red, warm, painful skin or open sores).
- Numbness, tingling, weakness, vision problems, or dizziness.
- Chills, swollen lymph nodes, night sweats, fever, or weight loss.
- Bruising, bleeding, and pale skin.
- Shortness of breath, swelling of ankles or feet, or sudden weight gain.
- Chest discomfort or pain, shortness of breath, joint pain or a rash on your cheeks or arms.

What Are Some Common Side Effects?

- Redness, rash, swelling, itching or bruising where the shot was given.
- Headache
- Runny nose

Tell your doctor about any side effect that does not go away in a few days or gets worse.

How Do I Use Rheutopia?

- Rheutopia is an injection (shot). Do not use Rheutopia until you have been shown how to give a shot.
- Store Rheutopia in the refrigerator. Do not shake or freeze.
- If you forget to take a dose, take it as soon as you remember. Take your next dose at your regularly scheduled time.
- Your doctor will tell you how often to use Rheutopia. Do not use Rheutopia more often than prescribed.

Where Can I Get More Information?

- Visit www.fda-more-information.gov
- Call 1-800-(manufacturer).

The Prototypes

Rheuptopia™ [Roo-toh-pee-ah] (also known as arixalate)

Important Warning: Serious Infections

- Rheuptopia affects the immune system. It can lower your ability to fight infections. Do not use Rheuptopia if you have an active infection.
- People taking Rheuptopia have gotten serious infections including tuberculosis (TB) and infections caused by viruses, fungi, or bacteria. Some people have died from these infections.

What Does Rheuptopia Treat?

- Rheumatoid arthritis in adults. Rheuptopia reduces painful and swollen joints, slows joint damage, and improves mobility and the ability to do physical activities.
- Polyarticular juvenile rheumatoid arthritis (JRA) in people older than 4 years of age who did not have good results from other medicines. Rheuptopia reduces pain, improves mobility, and decreases the number of painful joints.
- Ankylosing spondylitis. Rheuptopia reduces back pain, swelling, and improves mobility.
- Plaque psoriasis in adults who may benefit from taking medicine or receiving phototherapy (using ultraviolet light). Rheuptopia improves or clears up areas of skin with psoriasis.

What Should I Tell My Doctor?

- Before using Rheuptopia**, tell your doctor if you:
- have an infection, are being treated for an infection, or think you have an infection (such as a cold, flu or skin infection).
 - have TB or have been near someone who has TB. You may be tested and treated for TB.
 - lived in or traveled to other countries. There is more risk for getting TB or other infections in certain countries.
 - have any nervous system or heart problems.
 - are taking the medicine Kineret (anakinra). The risk of serious infections increased when used with Rheuptopia.
 - are scheduled to receive a vaccination (including a flu shot). You should not get a vaccination while taking Rheuptopia.

When Should I Call My Doctor?

Stop using Rheuptopia and tell your doctor right away if you develop:

- Fever, cough, flu-like symptoms, skin infection (red, warm, painful skin or open sores). These can be symptoms of a serious infection.
- Numbness, tingling, weakness, vision problems, or dizziness. Symptoms of nervous system diseases, like multiple sclerosis, may develop or get worse.
- Chills, swollen lymph nodes, night sweats, fever, or weight loss. You may have a higher chance of getting lymph node cancer.
- Bruising, bleeding, and pale skin may not make enough blood cells to help stop bleeding or to help stop bleeding.
- Shortness of breath, swelling, or sudden weight gain. These are failure that may develop or get worse.
- Chest discomfort or pain, shortness of breath, joint pain or a rash on your chest. These may be symptoms of an infection with lupus-like syndrome.

What Are Some Common Side Effects?

- Redness, rash, swelling, itching, or pain at the shot was given.
- Headache
- Runny nose

Tell your doctor about any side effect that does not go away in a few days or gets worse.

How Do I Use Rheuptopia?

- Rheuptopia is an injection (shot). Do not use Rheuptopia until you have been given a shot.
- Store Rheuptopia in the refrigerator or freezer.
- If you forget to take a dose, take it as soon as you remember. Take your next dose at the scheduled time.
- Your doctor will tell you how to use Rheuptopia. Do not use Rheuptopia if you are not prescribed.

Where Can I Get More Information?

- Visit www.fda.gov for more information.
- Call 1-800-338-2775 (manufacturer).

You may report side effects to (manufacturer) at (phone # and web address) or FDA at 1-800-338-2775.

Appendix B: Single Document Prototypes

DRAFT PROTOTYPE 3

Drug Approved by FDA: 2005
Date of Leaflet: May 2009

Rheuptopia [Roo-toh-pee-ah]

Active ingredient: arixalate

Uses

- Rheumatoid arthritis (adults and children older than 4): reduces painful swollen joints, slows joint damage and improves mobility
- Ankylosing spondylitis: reduces back pain, swelling, and improves mobility
- Plaque psoriasis in adults: clears up areas of the skin with psoriasis

Warnings

Important Warning: Serious Infections

Do not use Rheuptopia if you have an active infection. Rheuptopia affects the immune system and can lower your ability to fight infection. Some people have died from an infection such as tuberculosis (TB) when taking Rheuptopia.

Ask your doctor before using if you

- have any signs of infection (fever, cough, flu-like symptoms)
- have a skin infection (warm, red, painful skin or open sores)
- have tested positive for tuberculosis (TB) or have been near someone who has TB
- have a problem with your nervous system
- have recently been vaccinated or are scheduled to be vaccinated
- have lived or traveled outside the country
- have a problem with your heart
- are taking Kineret (anakinra)

Stop use and call your doctor right away if you

- have an infection (fever, chills, cough, flu-like symptoms)
- have a skin infection (warm, red, painful skin or open sores)
- have a skin rash
- have numbness (can't feel your skin) or tingling skin
- have changes in your vision
- have swollen lymph nodes, night sweats
- took more Rheuptopia than you were told to take
- have weakness in your arms or legs
- feel faint or light headed
- easily bruise or bleed
- get short of breath
- get swollen (fat) ankles
- have chest pain
- have sudden weight loss or gain

Report side effects to FDA at 1-800-FDA-1088.


Common side effects

- redness, rash, swelling, itching, or bruising where the shot was given
- headaches
- runny nose

Tell your doctor about any side effect that does not go away in a few days or gets worse.

PMI Activities, *cont.*

- Fall 2010 – Initiate public process on PMI Single-Document Solution
- Planned public workshop in conjunction with Brookings Institution
- Consumer Testing
 - FR Notice research protocol published 5/4/10; comment period closed 7/6/10
 - Initiate study following OMB approval Spring 2011
 - Test content compression, format and order of information
 - 150 face-to-face pre-screening encounters with consumers
 - Experimental design – 900 consumers with RA
 - Follow-up internet study – 200 consumers with RA



July 2010: Englewood Center for Health Care Reform at Brookings

http://www.brookings.edu/~media/Files/events/2010/0721_CMI/Final%20CMI%20discussion%20guide%20071910.pdf accessed

8/30/2010



Moving Forward

- Access and distribution – preliminary recommendations
 - Central e-repository of up-to-date leaflets
 - Permit e-receipt by the pharmacy
 - Pharmacy cannot change content or format
 - Permit the option for patients to receive leaflet electronically or in paper form (or other formats?)
- Process
 - Public/private consortium
 - Interim pilot solutions



Development and Distribution of Patient Medication Information for Prescription Drugs

- Register for the public hearing
 - email registration information to *PMIpublicmeeting@fda.hhs.gov*.
- Submit electronic comments
 - *<http://www.regulations.gov>*.
- Submit written comments
 - Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852
- A live webcast of this hearing will be viewable at
 - September 27 *<https://collaboration.fda.gov/p15d109272010/>*
 - September 28 *<https://collaboration.fda.gov/p15d209272010/>*

[Docket No. FDA-2010-N-0437]